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Summary Photodynamic therapy (PDT) and bio-nanotechnology (NT) show striking similarities
in clinical design and mechanistics. The PDT paradigm of photosensitizer application, light
activation and singlet oxygen generation does in fact occur on the nanoscale level as does
the resultant outcomes. NT has the ability to explain as well as modify each of the critical
steps of PDT particularly photosensitizer design and delivery, light source miniaturization and
optimization, location and intensity of the photodynamic reaction as well as offering a far
greater insight into dosimetry and mechanisms of action. This review will explore the current
and potential future interactions and modiﬁcations NT may have on PDT.
© 2008 Elsevier B.V. All rights reserved.
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Introduction
Just as life on Earth depends upon the successful transfer of
sunlight’s energy, human life depends upon the successful
transfer of molecules throughout our body. While the study
of light can be compartmentalized under the broad ﬁeld of
photonics, so too can the study of these cellular and subcel-
lular biological systems be studied under the emerging ﬁeld
of bio-nanotechnology [1,2].
While we may not recognize it, nanotechnology (NT) is
already widely at work, naturally [1]. A biological example
is evidenced in the transfer of lipids and proteins from, to
and between cells occurring at the nanolevel via the low
density lipoprotein (LDL) receptor system. Further, neural
transmission and likely memory is based on material stor-
age and degradation on the nanoscale particle level. Gene
expression is intimately involved in these nanoscaled pro-
cesses as well. Naturally occurring NT is alive and well and
plays a vital basic role for life and health [3].
As the name implies, bio-nanotechnology is the endeavor
that analyzes, develops, and implements synthetic and nat-
urally occurring tools measuring in size from approximately
1—1000 nm (though mainly 1—200 nm) and whose goal is to
explain and modify biological systems [4]. This less than
satisfactory deﬁnition is a result of the explosive emerging
knowledge concerning the physical, chemical and biologi-
cal behavior of these materials which remains to be better
deﬁned and reﬁned [5]. This study is further complicated by
the fact that the behavior of NT may very well change at
differing sizes on the nanoscale [6].
It is highly likely that NT will modify and alter both the
basic science and clinical applications of photodynamic ther-
apy (PDT). This review will summarize how this emerging
technology may change the face of PDT.
PDT—–current paradigm and shortcomings
For the last 100 years the treatment paradigm of PDT has
changed little [7]. A photosensitizing agent, when appropri-
ately activated by light, creates what is termed the oxygen
dependant photodynamic reaction (PDR). This ultimately
results in a system change, for example ablation of a lesion
without undue morbidity. To better understand the ramiﬁ-
cations of NT on PDT, we need to examine its current state
of the art.
Photosensitizers
Numerous naturally occurring and synthetic agents act as
photosensitizers (PS). Fundamentally these are deﬁned as
agents that produce singlet oxygen following light stimula-
tion [8]. However, in the clinical arena, few agents have
made it to the commercially available state, which impor-
tantly, allows patients to be treated of. Each of the handful
photosensitizers that currently are commercially available
has speciﬁc characteristics that can beneﬁt patients but
none are totally satisfactory [9—13] (Table 1). Depending on
the criteria used, the drawbacks of all these pharmaceuti-
cals can be summarized as having some or all of the following
shortcomings: inappropriate tissue half-lives causing difﬁ-
culty in optimizing illumination schedules; inappropriate
normal (or non-target) tissue retention so morbidity to these
bystanders can be signiﬁcant and of concern both during
and for prolonged periods post therapy; activation energies
requiring prolonged illumination times; dark toxicity; mini-
mally clinically useful wavelength severely limiting targeting
depth and equally important difﬁculty in synthesis and man-
ufacture of a product that is stable; minimally allergenic;
storable; easily reconstituted and cost effective. Still, even
with these serious issues and shortcomings, clinical success
is routinely possible. Nanotechnology may be a means to
reﬁne these molecules for improved PDT.
Table 1 Current PS drawbacks
•Hydrophobicity
•Difﬁculty in synthesis
• Suboptimal half-life
• Lack of speciﬁcity
•Normal tissue uptake
•Dark toxicity
• Suboptimal activation energy
• Suboptimal wavelength for activation
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Table 2 Current illumination drawbacks
• Localization difﬁculties
• Fluence non-optimization
• Size of light source
• Flexibility of light source
•Timing of illumination
•Cost of light source
• Energy needs of light source
Light sources
A myriad of light sources, including the sun (often uninten-
tionally) can reproducibly activate photosensitizers [14,15].
A major PDT advance has been seen through technology
with the continuing reﬁnement of commercially available
and reliable illumination devices. Filtered ﬂuorescent lights,
portable diode lasers and more recently, light emitting
diodes (LED) devices speciﬁcally designed and adapted for
PDT, are available worldwide [16]. With the expanded imple-
mentation of ﬁber optics as well as miniaturized scopes and
delivery systems even the most deep seated tumor beds
can be theoretically illuminated [17]. However, even with
these progressively improved devices, illumination remains
relatively inaccurate and poorly monitored (Table 2). Any
pigmented particle can block the bulk of lights transmission
and current devices have no means to identify this. Fur-
ther, light dosimetry reveals rapid fall off at most angles of
incidence. Crevices, tissue and surface irregularities lead to
inhomogeneous light distribution, a likely critical cause of
under and/or over treatment. Current devices are a magni-
tude better than the earlier devices, but certainly nowhere
near what is required to optimally achieve homogeneous or
intentionally modulated illumination. NT may offer these
possibilities.
Photodynamic reaction
The basis of a therapeutic outcome in conventional PDT
is the creation of the PDR [18]. Here, a type II oxidative
reaction creates various free radicals and most importantly
singlet oxygen; all may induce necrosis, apoptosis or both.
Many photosensitizers accumulate in vascular membranes,
cell membranes, organelle membranes or in a combination
[19]. Following light activation and PDR, these membranes
are critically damaged or destroyed with release of contents
[8]. Potentially, one may see a rapid vascular shut down,
release of cytokines with downstream immunologic reac-
tion or even programmed cell death induction. Certainly
exploiting the location and intensity of these components
could offer signiﬁcantly different clinical outcomes rang-
ing from the equivalence of a vaccine to an extremely
Table 3 Current PDR drawbacks
• Location non-speciﬁcity
• Intensity non-speciﬁcity
•Downstream and normal tissue toxicity
•Poor dosimetry
localized treatment [20]. Currently, clinicians appear to be
concentrating on lesion ablation without undue morbidity
and not attempting to exploit these potential reﬁnements
(Table 3).
Dosimetry
An underappreciated aspect of any treatment is the control
of the photodynamic reaction to allow for maximal lesion
ablation with minimal normal tissue toxicity [21]. The key to
maximizing outcome is by a reliable dosimetry system that
accounts for all relevant variables in a therapy. This dosime-
try system would guide and reﬁne treatment. The effects
and side effects of radiation therapy are highly predictable
due in part to an accurate dosimetry system based on the
interaction of radiation and matter. No such reliable sys-
tem exists for PDT. Rather a crude, yet somewhat successful
system involving administered drug dose, DLI (drug infusion
to light illumination interval) and light ﬂuence (in a rough
calculation) remains the mainstay of dosimetry. No feed-
back on an individual’s PS concentration, normal tissue as
well tumor bed concentration, actual illumination ﬂuence,
oxygen level, singlet oxygen production or any of perhaps
a dozen other variables are routinely employed. Using the
same drug, same infusion dose, same light dose and same DLI
result in widely disparate outcomes even in the same patient
who may have multiple lesions. Some patients respond well,
others minimally, due in large part to an archaic, inefﬁ-
cient dosimetry system. Until accurate real time dosimetry,
with built in feedback, is developed and brought to com-
mercial status excellent and reliable clinical outcomes for
PDT will remain out of reach. There are in the last few
years renewed efforts to improve the dosimetry in PDT
[22,23]. As we shall see, NT may play a crucial role in this
arena.
Nanotechnology
Nanotechnology has the great potential to alter each critical
component of PDT to ultimately allow for clinical and scien-
tiﬁc advances. While not widely recognized, NT is already in
use in PDT and may ultimately help explain the mechanisms
of PDT. However, prior to exploring nano-PDT, a brief review
of NT as it applies to medicine is required.
Safety
It is established that NT occurs naturally in the body. Simi-
larly, NT exists naturally in the earth’s environment [24,25].
Nanoparticles (NPs) are created after lightning strikes and
have been found in glacial ice dating back eons. NPs have
also been found in meteorites, providing a universal con-
nection. While this may offer some comfort for safety, these
naturally occurring levels are far fromwhatmay be expected
with widespread industrial synthesis and introduction to the
environment. As a cautious example: soot, a NP produced
from incomplete carbon based combustion, is quite capable
of aerosolization, widespread atmospheric transfer across
continents and transfer deep into themammalian pulmonary
system generating signiﬁcant toxicity potential [26]. While
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one can argue that limited NP production and use in the
biomedical sciences outweigh potential risks, the current
state of the art on safety is in its infancy. Further, the major-
ity of NP production has been industrial based and there too,
signiﬁcant safety issues and environmental laws governing
release are lacking so far.
Efﬁcacy
As naturally occurring NT in our body is a prime exam-
ple of the bounty, simplicity and ultimate efﬁcacy of these
processes it would seem appropriate to try to mimic and
design clinically relevant NT for the diagnosis, treatment
and potential prevention of disease. Among the NT bioin-
dustrial uses is the creation of simpler synthetic processes
for production of pharmaceuticals [27], controlled systems
for degradation and release of chemicals and molecules
[28,29], detoxifying agents [30], and biosensors able to
detect miniscule amounts of various substances including
poisons [31,32].
Nanoparticles types
By deﬁnition these are structures between 1 and 100 nm
[25,33]. However when these structures combine they
may be larger than this deﬁnition. Complicating the NT
ﬁeld is that size generally determines physical, chemical
and biological activity so when these structures combine,
their characteristics likely change [34]. In general, NPs are
deﬁned ﬁrst as being either naturally occurring or synthetic
and then subclassiﬁed as being organic (carbon containing)
or inorganic (Table 4). Subsequent classiﬁcation is generally
based on structure (sphere, tube, etc.) and what they may
contain such as oxides, metals or salts that are critical to
function. Some examples of naturally occurring, organic NP
includes soot, colloids, aerosols, and even viruses. Synthetic
NP examples include catalysts used widely in chemistry and
probes encapsulated by biologically localized embedding
Table 4 Nanoparticle classiﬁcation
•Natural versus synthetic
•Organic versus inorganic
•Attribute
Oxide
Metal
Salt
Polymer
Aerosol
Other
• Structure
Colloid
Quantum Dot
Fiber
Rod
Crystal
Fullerene
Other
(PEBBLEs) designed speciﬁcally to advance the ﬁeld of pho-
tonics [35].
Tools
For biomedicine NT tools may be broken into two broad
categories: devices for diagnosis (sensors) and devices
for therapy. Perhaps, nanorobots may one day accomplish
both.
Diagnostics
At this point, tools for diagnosis are various nanosensors
and probes that may be used at the cellular and subcellular
level to help gain understanding of both the normal and dis-
ease process at this fundamental level [31,36,37]. Examples
of nanoprobes to help deﬁne chemical process and mecha-
nism of molecular response are becoming widespread in the
biological, chemical and physical sciences [31]. One com-
mon application is NT on a chip. The chip may be designed
to indicate or analyze DNA, proteins, immunoassays among
many other categories. The NPs can also be designed to
tag onto stem cells, bacteria, viruses, normal and malig-
nant cells to act not only as a detector but also as tracking
devices. Applications include observation of cell maturation
and travel, use as a biomarker for presence or absence of
a particular bacteria, virus or speciﬁc metabolic pathway
activation. This later use can signal a cell’s transformation
to the malignant state. By blocking this activation perhaps
a novel treatment can be deﬁned.
As these are nanoscale tools, one can identify single cells
and molecular pathways in great detail leading to impor-
tant advances in basic science. Bio-Bar-Code assays [38] use
various NP to detect multiple different normal and abnor-
mal pathways simultaneously and will likely, as an example,
allow for one drop of blood to be used to replace chemistry
panels that currently take several vials.
Whereas prior to NT many probes were too large to allow
these processes to be directly observed and analyzed with-
out signiﬁcant disruption, NT may have diminished if not
solved this problem. This is emerging on several fronts.
One successful pathway has employed gold NPs which can
be attached to DNA down to 10 nm in size [37]. The gold
is easily identiﬁed and allows tracking of millions of dif-
ferent DNA sequences simultaneously. Quantum Dots (QD)
are inorganic ﬂuorophores that due to their NP size allow
for introduction into and on the cell without disruption
of normal processes [37]. By attaching the QD to normal
and tumor cells, observation on normal and tumor physiol-
ogy is possible, allowing the determination of differences
between these processes. QD have also been designed to
detect viruses and bacteria in real time, certainly of great
use to an ill individual whose medication choice and survival
may depend on rapid diagnosis [39]. But also it may be of
great use in the case of bioterrorism in which tiny amounts
of poisons can be detected in air, water or food. By design-
ing paramagnetic, pH sensitive or electrically sensitive NP,
one can also direct these sensors to particular anatomical
regions. As mentioned, PEBBLEs are NP platforms that can
be designed as highly accurate sensors to measure intracel-
lular and extracellular ion levels (such as Na+, K+, Cl−, Ca+,
etc.) as well as oxygen, OH radicals and even singlet oxygen
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[40], clearly of great importance to understanding cellular
reactions and in particular, to understanding of PDT and PDR.
Since PEBBLEs are on the nanoscale size they do not neces-
sarily interfere with the naturally occurring processes of the
cell as prior, larger scaled sensors typically had, thus open-
ing the door to a greater understanding of many activities,
not just PDT.
Therapy
Multiple options exist to create NP of various sizes, shapes
and materials that can impact organic processes [37]. Cur-
rently, most NP oncology research is based on creating NP
to bind and enter cells at very speciﬁc sites and recep-
tors. For the most part these attempts are based on a
desire to achieve transfer of a pharmaceutical such as a
chemotherapeutic agent into a speciﬁc targeted cell, usu-
ally one transformed to the malignant state. The goal is to
allow a highly targeted, lethal event while sparing surround-
ing normal cells. On a more sophisticated level the NT agent
may also be designed not only to apply a lethal dose but also
to prevent the cell from using a detoxifying method. With NT
design, so long as the appropriate pathway and entry point is
clearly deﬁned, a lethal intervention may be created. Simi-
larly, premalignant cells, expressing, for example, abnormal
proteins, again an abnormal pathway that must be deﬁned,
may be targeted by appropriately designed NP. Further, NP
may be carriers for a pharmaceutical or may be lethal on
their own, again depending on NP design. Gold NPs can be
heated by light energy to create a tumoricidal hyperther-
mia effect [41]. An additional aspect is that the NP, usually
designed as a QD, can also be measured and correlated with
disease progression or response.
PEBBLEs have recently begun to play an important role
in intervention [40]. The same platforms that were created
to load sensors can be loaded with photosensitizers, imag-
ing dyes, even singlet oxygen along with a myriad of other
molecules that may offer therapy. The PEBBLEs platform
can also be designed for binding to speciﬁc antigens or cell
receptors that can direct this molecule precisely to a speciﬁc
target.
Nanorobots
Ultimately, as NT progresses it would seem likely that a
device could be created that monitors and detects abnor-
malities and then intervenes to attempt restoration. A
feedback loop would be needed to ensure complete ther-
apy. While not nanoscale, consider clinical PDT: a drug is
introduced; light is brought in for a determined time and
lesion destruction accomplished. The paradigm is set. Only
the appropriate tools are needed on a nanoscale. Potentially
a nanoscale PDT would be possible to destroy malig-
nancy, infection or even allow for a regenerative medical
process.
Nano-PDT
As we can see NT may have a great impact on each step of
PDT. We will now examine the current state of the art and
how it may alter the science and practice of PDT.
Photosensitizers
It should come as no surprise that NT is already directly
involved with PS [20]. Any PS that is brought into cellular or
subcellular membranes likely has been taken in by NP sized
receptor molecules. PSs that are intravenously introduced
do not travel far before the body detects and binds these
molecules. Generally, binding is by the lipoprotein system
of the plasma consisting of albumin or LDL. The immune
system macrophages may ingest these foreigners, or the
NP—PS complex may continue to travel. A common and rou-
tine means exploited by commercial pharmaceuticals is to
encapsulate therapeutic substances into lipoproteins, par-
ticularly VLDL (very low density lipoprotein). As fats and
proteins are required to allow for the excess metabolism
and reproduction of malignant cells (and normal cells with
high turnover) this encapsulation is a reliable way to tar-
get these regions. It is highly likely an identical mechanism
brings the current generation of PS to its target as well. The
NP—PS complex may then enter the target by various means.
Photofrin® is composed of porphyrin monomers, dim-
mers, and oligomers. The smaller components appear to
be taken into the cell passively by diffusion, ultimately
to the mitochondria. The larger often are actively brought
into plasmamembranes by phagocytosis. All components are
needed for clinical success [18]. Mono-N-spartyl derivative
of chlorin e6 (MACE) is actively brought to the lysosomes
by endocytosis [42,43]. The phthalocyanines speciﬁcally
accumulate in mitochondria [19]. Benzoporphyrin deriva-
tive (BPD) accumulates in the Golgi apparatus [20]. When
amino levulinic acid (ALA) is introduced in tissue it is
transformed to protoporphyrin IX and may localize in cell
membranes (monomer) and lysosomes/mitochondria (aggre-
gates). Therefore, it also appears clear that current PS can
accumulate preferentially in different subcellular compo-
nents by naturally occurring processes on the NP scale.
In this naturally occurring NP—PS complex virtually all
tissues may accumulate this NP—PS complex. However, as
previously mentioned rapidly proliferating tissue see this
lipoprotein NP—PS as a form of energy so preferential
accumulation occurs in this manner. Additional selective
accumulation occurs as tumors have increased lipoprotein
receptors. The leaky neovasculature of tumors may also
favor accumulation and diminished clearing. What is also
important to consider is that once the PS is activated
and generates singlet oxygen a rapid destruction of cel-
lular organelles occurs. Therefore, the PS accumulated in
the mitochondrial membranes may then be redistributed
throughout the cell and cytoplasm. As illumination will
still be occurring, the PS may now generate singlet oxy-
gen in new locations. If the PS was in the cell membrane
and this resulted in destruction, the PS may now travel to
interstitial regions or microvasculature and generate singlet
oxygen here. Therefore, in reality one already has achieved
a NP—PS complex for very speciﬁc delivery; however, ulti-
mately where the PS actually ends up (particularly during
illumination) may vary dramatically. This has important ram-
iﬁcations for NP—PS where rational design is employed for
speciﬁc PS localization.
NP—PSs constructs are well underway and follow sev-
eral pathways [40,44]. Naturally occurring NP likely assist in
the delivery and uptake of current PS into the membranes
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and cells organelles. Synthetic, designed NP will have a fur-
ther reach. Many naturally occurring and synthetic PS are
hydrophobic. This means they reconstitute poorly, have dif-
ﬁculty traveling in biological systems and may be rapidly
cleared by the reticulo-endothelial system (RES) (lymphatic)
of the body. By creating NP to encapsulate or attach to
current or innovative PS the NP become the critical struc-
ture for tissue delivery. Appropriate NP design therefore can
have a very far reach where PSs are concerned. By ratio-
nal design, speciﬁc tissue half-life, targeting, avoidance,
immune tolerance, and hydrophilicity, among other char-
acteristics, can be created as the shell for these new PS or
as a means to modify current ones. The actual size of the
NP appears critical. NP > 200 nm can be taken up by the RES
of the immune system. Smaller NPs appear able to travel to
their destinations generally undetected by immune surveil-
lance. One should recall though that NP can bunch together,
so even those designed at the smallest end of the spectrum
may behave far differently in vivo [45,46]. Further, the NP
can have speciﬁc additions such as monoclonal antibodies
for potential greater targeting and even additional imaging
agents attached to allow better visualization by CT scan,
MRI, or PET. In addition to PDT, paramagnetic attachments
(for MRI) could also be spun for local hyperthermia. It should
be emphasized that by design of the NP one can circumvent
natural barriers to drug delivery such as the skin, pulmonary
system, blood—brain barrier—–even the nuclear membrane.
One can also prevent the uptake of the drug by the immune
system and how it clears the body to avoid, for example,
the liver or the kidneys [47]. Imagination appears to be the
limit but so far clinical evidence is lacking (Table 5).
Encapsulation of PS by NP
The characteristics of the NP will determine the biologi-
cal and pharmacokinetics of the molecule. Encapsulation is
well established in the pharmaceutical industry where, for
example, lipids via NP emulsions are commonly employed.
This is likely already accomplished when the clinical PS
Purlytin (SnET2) is reconstituted in an emulsion. As this PS
showed excellent clinical selectivity, intentional encapsula-
tion via emulsion (a NP) shows proof of principle. A number
of different techniques for encapsulation exist with PEBBLEs
technology [48,49]. These techniques also result in highly
concentrated packets of PS within the NP. Using PEBBLEs,
Kim et al. [48] embedded Indocyanine Green (ICG) into an
organically modiﬁed silicate (ormosil) NP. ICG has the advan-
tage of FDA approval and activates at about 800 nm for
excellent tissue penetration. This dye may also have two
photon PDT characteristics [50] and can readily ﬂuoresce.
ICG alone is hydrophobic and clears too rapidly to be an
effective PS on its own. ICG-PEBBLEs had excellent charac-
teristics for both imaging and therapy. When encapsulated
by poly lactic-co-glycolic acid (PLGA) NPs the PS activ-
Table 5 NP—PS opportunities
• Synthesis
• Speciﬁcity
•Variable half-life
•Coupling
ity remains but half-life characteristics became clinically
viable. When using PLGA polymers as NP the NP—PS complex
appears to be very selective as a drug delivery system as well
[51]. Similarly Kim et al. [49] encapsulated the highly active
PS HPPH (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-
alpha or Photochlor) with dye containing ormosil NP. This
allowed for conjugations enhancing two photon PDT. NP
polyacrylamide (PEG) encapsulated methylene blue as a PS
or Photofrin® as a PS showed both excellent imaging capa-
bility and PDT on a single encapsulated platform [52]. When
iron oxides were incorporated as well, the potential for local
toxic heating via magnetic resonance was demonstrated.
Encapsulation with PGGA NPs altered the hydrophobic states
of the highly efﬁcient PS bacteriochlorophyll and achieved
high concentration of the PS in a simple technique [53].
Dyes are a rich source of PS but those used clini-
cally had prolonged tissue retention—–potentially in the
skin for several months of photosensitivity. By NP encap-
sulation with PEG-coating, zinc phthalocyanine prolonged
tissue half-life could be modiﬁed extensively [54,55]. Ricci-
Junior and Marchetti [56] reported NP-zinc phthalocyanine
had numerous improved characteristics for drug delivery.
In a CAM (chick chorioallantoic membrane) model Pegaz et
al. [57] reported NP encapsulation of Verteporﬁn allowed
for greater targeting than non-NP encapsulation. NP emul-
sions of meso-tetra-(4-hydroxyphenyl) porphyrin (p-THPP)
allowed for improved tumor uptake in vitro via a simple
synthetic process [46,58].
Surface bound PS
In this design, the PS appears to remain on the surface of
the NP, but the NP itself still dictates pharmacokinetics [59].
Theoretically, the singlet oxygen would be more available
when generated from the surface than from diffusing within
a NP [60]. In a study by Wieder et al. [61], gold NP was
attached to the PS phtalocyanine via a thiol moiety. Synthe-
sis allowed for the hydrophobic PS to behave hydrophilically
with excellent PDT.
NP conjugating PS with additional tools
It should be clear that NP design signiﬁcantly inﬂuences
biological, physical and chemical characteristics of the PS.
Intentional design and attachments of additional moities
to the NP can also inﬂuence behavior. As an example iron
containing NP allows for both PDT and hyperthermia [62].
Antibodies have also been attached to NP—PS. By selecting
an antibody to speciﬁc targets seen only in malignant cells
further selectivity may be possible [63,64]. NP-Verteporﬁn
conjugated to VEGF (vascular endothelial growth factor)
antibodies showed additional selectivity in a CAM model
[65]. Additional antibody targets such as PSA (prostate) and
HER-2 (breast) have been explored. The placement of mag-
netic particles within the NP—PS to allow an externally
directed means to bring the PS to the target has also shown
preliminary success [64,66,67].
NP conjugated with biosensors and PS
This concept would allow for monitoring of the PS reaction
and with appropriate telemetry give signiﬁcant feedback on
the treatment. In its simplest form, a change in ﬂuores-
cence, if possible monitored in real time, would allow for
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Table 6 NP illumination opportunities
• Less expensive
•More ﬂexible
•Matched to speciﬁc PS
•Uptake with PS
• Lack of external light source
•Optimal timing programmed
extrapolation to treatment success (or failure) and improve
therapy dramatically. If the biosensor had a feedback loop it
could even stop therapy when the targets were destroyed.
NP alone
It is clear that theoretically NP can be designed to have
very great speciﬁcity and activity. Perhaps a singlet oxygen
generating NP designed to attach to malignant or abnormal
cells, will eventually be all that is really needed. Possibly
this would not deﬁned be as PDT.
Illumination
Currently various devices supply the light energy required
to activate the photosensitizer. Illumination is in fact con-
sidered a separate component of the clinical PDT paradigm.
NT may alter this signiﬁcantly (Table 6). First NT may sig-
niﬁcantly improve current illumination devices. Lasers are
precise, expensive and are also relatively large in physi-
cal dimension as sources of illumination. NT will decrease
the cost of production and the size of many light sources.
This could allow for prolonged or metronomic PDT. More
likely NT will improve diodes as to allow these illumination
devices to become pre-eminent. Current LED’s are tradi-
tionally based on semiconductor technology using inorganic
structures such as silicon. These are less expensive to pro-
duce than lasers but not as precise a source of illumination.
The actual LED device remains relatively large, and can be
far larger and inﬂexible compared to current ﬁber optics.
With NT organic-light emitting diodes (O-LED’s) are possible
[68]. Here, organic chemicals can be deposited on various
substrates such as a ﬁlm and when current is introduced very
precise illumination of a speciﬁc wavelength or a spectrum
can be generated depending on design. In this paradigm,
custom illumination sheets could be created for a speciﬁc
patient who needs large cutaneous therapy just as eas-
ily as a pinpoint light ﬁlm placed in a deep seated tumor.
Biodegradable OLED’s which would harmlessly dissolve upon
completion of illumination could be ideal. With very low
electricity needs, battery operated LED and O-LED devices
are possible, allowing ﬂexible illumination schedules even
in third world conditions.
A second alteration in illumination is possible with NT.
NP design may also directly enhance illumination, a concept
particularly useful for deep seated lesions. Packets of metal-
lic NP can be designed to concentrate in the target tissue,
along with the PS. This can create a light cavity in which,
by deﬁnition, illumination intensity will increase manifold.
For surface lesion illumination far less PS and light energy
would be required for successful outcome. More important,
deep seated lesions could be treated by infrared (IR) light
which, while deeply penetrating, is on its own too weak to
activate a conventional PS. However, with the NP creating a
light cavity a PS with two photon PDT could readily activate.
This has signiﬁcant clinical ramiﬁcations. Further, the metal-
lic NP could be heated by the IR. Such studies are underway
in Brazil and elsewhere [69]. Another possible effect to be
studied would be the plasmonic effect of NP to produce local
heating and killing of tissue by hyperthermia.
A third possibility would be to create nanoscale light
sources. Interestingly, many materials that have poor lumi-
nescence can actually have signiﬁcant light emission when
designed as NPs, thus opening the door to innovative light
sources [70]. Potentially, NPs will be employed as the illu-
mination agent, as a means to deploy illumination, as a light
squelcher or as part of a larger NP complex containing the
PS agent.
Conceivably, the NP itself is devised to ﬂuoresce or lumi-
nesce at a particular wavelength matching the PS [71]. As
the illumination is in fact within nanometers or microme-
ters of the PS no great need for deeply penetrating longer
light wavelengths would be required. In fact most of the
currently available PS activate most effectively at the Soret
band (400 nm). Thus the intimate interaction of light with
PS at 400 nm would be a means to enhance PDT both via
greater efﬁciency of singlet oxygen production and likely
result in less need for PS as well. Alternatively, lumines-
cence could be induced by an external energy source to
ultimately activate the PS. Luminescence NPs of both short
and long half-life (afterglow) exist that emit light from about
400—700 nm and can also be matched to a particular PS
[72,73]. In this paradigm external energy from, for example,
radiation is absorbed by the NP leading to luminescence. As
long as the NP light emission is matched to the PS a PDR can
occur [74]. Luminescence can also be created by transfer
from other energy sources such as heat. An optimal design
would be via NP that bind to speciﬁc sites as needed (mem-
brane, organelle, etc.) and the actual binding would alter
the NP structure so that illumination would be initiated. The
binding would set off a series of reactions that create the
energy for illumination. The binding could set off reactions
that generate heat for hyperthermia or radiation as well
[62].
NP as illuminating agents
The NP illuminating agent may be administered separately
from the PS. This would allow the PS to accumulate in the
desired region and clear ‘‘normal’’ tissue. The paradigm
would then be a NP that generates appropriate illumina-
tion/luminescence at a clinically relevant wavelength to
activate the PS. Ideally the NP would be designed to have
similar targeting speciﬁcity as the PS for even greater selec-
tivity of intervention localization. Light emission could be
controlled with design of luminescence for shorter or longer
intervals as clinically indicated.
NP to deploy illumination
Naturally ﬂuorescing and luminescing agents can be
attached to the NPs that are designed for speciﬁc tissue
targeting. Therefore the NP is a means to transport the
illuminating agents. These agents may be self-activating or
activated by external energy sources such as radiation, heat,
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Table 7 PDR NP opportunities
•Biosensors
• Squelching
•Dosimetry
•Two photon PDT
• Localization
or magnetic ﬁelds. As an example, those activated by radia-
tion would travel to their destination, and also, likely travel
to other anatomical regions but in lower quantities. However
as radiation (by external beam therapy for example) serves
as the source of activation energy and would only target
the tumor bed in question no PDR would be generated out-
side this beam. As radiation penetration and dosimetry is
well deﬁned this may be a means to provide a more pre-
cise photodynamic therapy in combination with radiation
therapy.
Squelching agents
Ideally light or free radical squelching agents could be cre-
ated and delivered by NP to preferentially absorb in critical
normal tissues. This photo protector may then enhance the
therapeutic ratio by allowing more intense therapy to the
abnormal tissue which does not contain much squelching
agent.
Combined illumination/PS NP
Here, one NP containing both the illuminating and PS agent
would be synthesized. If developed, with accurate targeting,
this NP would allow for a rapid one stop treatment. While
theoretically attractive, having an activated light source in
combination with the PS from the beginning of synthesis of
the NP may lead to rapid degradation of the PS, uninten-
tional PDT to all tissue as the NP is traveling, and excess
PDT to tissues that clear and eliminate the NP. This may
be solved by creating an illumination NP requiring an addi-
tional energy source for activation such as radiation, heat
or magnetic induction.
Summary
Illumination is a major difﬁculty in current PDT and NP may
well improve this aspect. However unintentional PDT to tis-
sues traveled and tissue eliminating the illuminating NP may
be a consequence. Using an outside source of activation
energy such as radiation or magnetic ﬁeld may be possible
but this assumes that devices such as linear accelerators and
magnetic resonance imaging (MRI) are readily available with
appropriate dosimetry and anatomical localization. This is
an unrealistic expectation in most parts of the world. On
the other hand, ultrasound devices may offer an outstanding
potential as the energy source to activate illumination par-
ticularly as these sophisticated, precise and powerful tools
are cost effective and available worldwide.
Photodynamic reaction
No doubt NP already plays a key role in the PDR (Table 7).
Classically, highly reactive singlet oxygen species are cre-
ated by the interplay of light energy and the PS leading
to cellular and subcellular responses mediated by naturally
occurring NP. The actual location of PS concentration can be
further pushed by design of the NP. Routes favoring speciﬁc
cell membranes or organelles can be created. This could
allow for apoptotic runs if the PDR were pushed entirely
intracellularly or for more systemic/vascular outcomes if
the PDR were pushed to the cell/vascular membranes
exclusively. Of note, currently PDT is not felt to be carcino-
genic/mutagenic due to the lack of direct action on DNA. If
NP were designed to bring the PS into the cell nucleus, PDT
might then become even more efﬁcient as DNA is exquisitely
sensitive to free radical damage, but at the potential cost
of creating second malignancy.
This direct singlet oxygen reaction may not be the entire
photodynamic process. Mounting evidence indicates that
two photon absorption (two photon PDT) may be a com-
ponent in clinically relevant outcomes. In this case the
photosensitizer also is activated by ﬂuorescence resonance
energy transfer (FRET) generated from the PS, naturally
occurring ﬂuorophores or introduced dyes [49]. Additionally,
in two photon PDT more penetrating (longer wavelength)
light may initiate the PDR allowing for deeper tissue
penetration. As previously mentioned, NP-photosensitizers
favoring two photon reactions have been created; therefore,
the PDR can also be manipulated in another sense via NP. As
free radical production remains the key ingredient, conceiv-
ably this type II reaction can be created directly without the
need for illumination, directly via appropriately designed
nano-molecules (not PS) that emit singlet oxygen. Likely this
would not be called PDT.
Dosimetry
NP can play a key role. Using PEBBLEs technology nanoplat-
forms that can advance the ﬁeld of PDT are now available
[48]. One particularly interesting application of PEBBLEs
technology was to create a nanolevel singlet oxygen sensor
[40]. Traditionally, these constructs were too large to use at
the cell level, too cumbersome to offer accurate measure-
ments and unable to routinely be used in both hydrophobic
and hydrophilic environments. The dye used to measure sin-
glet oxygen production was also toxic to the cell. Singlet
oxygen nanoprobes were created using PEBBLEs technol-
ogy that overcame each of these serious issues. The toxic
dye used to measure singlet oxygen production was success-
fully embedded within the NP to eliminate toxicity and the
construct of the NP was such that it allowed successful accu-
rate singlet oxygen measurement within a variety of cells
and environments [75]. Appropriately designed nanosensors
could monitor oxygen level, PS level, free radial production,
cytokine response, assay for DNA/RNA/protein damage,
among a myriad of other relevant variables. Particularly
important could be real time monitoring of light transmis-
sion, absorption and scatter to give feedback on this critical
aspect of therapy. These devices could be used both in vitro
and in vivo to allow for a signiﬁcantly improved understand-
ing of the basic and clinical science involved with PDT and
photodiagnosis. Even if some of these variables could be eas-
ily monitored in a real time basis no doubt clinical dosimetry
could make a quantum leap forward. These nanosensors,
which have the great potential to assay without disrupting
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the natural biological process, could be one major advance
PDT has been waiting for.
Conclusion
Clearly NT is a highly efﬁcient naturally occurring process
and just as clearly NT is already a part of PDT. The road
ahead that creates a fully operational NT-PDT paradigm will
allow for far greater understanding of the critical steps
so poorly deﬁned in our current use of PDT. The potential
to improve PS, illumination, PDR and dosimetry, appears
to be a fundamental possibility through NT. However, just
as PDT promised to be revolutionary, the same revolution-
ary expectation associated with NT will likely calm itself
and move forward in an evolutionary fashion. The same
difﬁculties to create a commercially available NT PS exist
as for current PS. This is even more apparent in the use
of NT illumination concepts. Certainly, though, the emer-
gence of NT biosensors is critical for our understanding of
the PDR and development of dosimetry. With NT we may
ﬁnally bring PDT to the forefront of oncological diagnosis and
intervention.
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